Challenges Of Moving A Bioconjugate Candidate From Clinic To Market

A novel drug’s path to market is complex and uncertain. Drug developers must successfully navigate the journey, under the growing pressure of regulation and competition, and while carefully managing technical and financial risk.

Beyond the challenges of gaining regulatory approval, transitioning production and scaling up from a clinical to commercial scale, and planning for the capacity to meet market demand, going to market with a bioconjugate or ADC candidate involves additional complexity. These biotherapeutics comprise multiple, different components, so their manufacturing and highly complex supply chains require specific know-how and capabilities to succeed in commercial settings.

In this webinar, we explore the particular challenges when moving a bioconjugate candidate from clinic to market. Our experts share key considerations and pitfalls to avoid along the way. Several customer case studies will illustrate concrete solutions about how Lonza’s expertise and integrated solutions have helped drug developers bring their innovative therapeutics to market.